277 related articles for article (PubMed ID: 16304269)
61. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
Carratalà J; Fernández-Sabé N; Ortega L; Castellsagué X; Rosón B; Dorca J; Fernández-Agüera A; Verdaguer R; Martínez J; Manresa F; Gudiol F
Ann Intern Med; 2005 Feb; 142(3):165-72. PubMed ID: 15684204
[TBL] [Abstract][Full Text] [Related]
62. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
63. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
64. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
65. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Enzweiler KA; Bosso JA; White RL
Pharmacotherapy; 2003 Jul; 23(7):925-32. PubMed ID: 12885105
[TBL] [Abstract][Full Text] [Related]
66. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.
Paladino JA; Adelman MH; Schentag JJ; Iannini PB
Pharmacoeconomics; 2007; 25(8):677-83. PubMed ID: 17640109
[TBL] [Abstract][Full Text] [Related]
67. [Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients].
Karwat KJ; Grabczak M; Chazan R
Pneumonol Alergol Pol; 2006; 74(1):77-9. PubMed ID: 17175982
[TBL] [Abstract][Full Text] [Related]
68. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Milkovich G
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523
[TBL] [Abstract][Full Text] [Related]
69. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study.
Kuzman I; Daković-Rode O; Oremus M; Banaszak AM
J Chemother; 2005 Dec; 17(6):636-42. PubMed ID: 16433194
[TBL] [Abstract][Full Text] [Related]
70. Economic cost of community-acquired pneumonia in New Zealand adults.
Scott G; Scott H; Turley M; Baker M
N Z Med J; 2004 Jun; 117(1196):U933. PubMed ID: 15280937
[TBL] [Abstract][Full Text] [Related]
71. Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.
Berger A; Edelsberg J; Oster G; Huang X; Weber DJ
Am J Med Sci; 2014 May; 347(5):347-56. PubMed ID: 24029796
[TBL] [Abstract][Full Text] [Related]
72. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.
Ramirez JA; Cooper AC; Wiemken T; Gardiner D; Babinchak T;
BMC Infect Dis; 2012 Jul; 12():159. PubMed ID: 22812672
[TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
Wessels F; Anderson AN; Ebrahim O
S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
[TBL] [Abstract][Full Text] [Related]
74. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia.
Leyenaar JK; Shieh MS; Lagu T; Pekow PS; Lindenauer PK
Pediatr Infect Dis J; 2014 Apr; 33(4):387-92. PubMed ID: 24168982
[TBL] [Abstract][Full Text] [Related]
75. Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial.
Rubio FG; Cunha CA; Lundgren FL; Lima MP; Teixeira PJ; Oliveira JC; Golin V; Mattos WL; Mählmann HK; Moreira ED; Jardim JR; Silva RL; Silva PH
Braz J Infect Dis; 2008 Jun; 12(3):202-9. PubMed ID: 18833404
[TBL] [Abstract][Full Text] [Related]
76. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
[TBL] [Abstract][Full Text] [Related]
77. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus.
So W; Crandon JL; Nicolau DP
Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307
[TBL] [Abstract][Full Text] [Related]
78. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
79. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
80. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
Bhavnani SM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
